DDMAC letter-writers off to a busy start of 2010

Share this article:
DDMAC cites fishy Cymbalta fibromyalgia ads
DDMAC cites fishy Cymbalta fibromyalgia ads
The FDA's Division of Drug Marketing, Advertising and Communications got off to a busy start in January.

The agency released a new batch of enforcement letters, bringing its tally for the month to nine. All were “untitled letters,” somewhat less serious than “warning letters.”

The most recent posted, issued on the 27th, said patient videos and a website for Lilly and United Therapeutics' Adcirca were false and misleading – the site because it omitted risks associated with the pulmonary arterial hypertension drug and the patient videos because they overstated efficacy. Another letter, not yet released, went out to Takeda on the 28th for Rozerem promotions, and a letter was issued on Aricept marketing yesterday.

Other letters went to: Sanofi-Aventis, for a BenzaClin patient brochure; Meda Pharmaceuticals, for a waiting room sign touting Astelin Nasal Spray; and Novalar Pharmaceuticals, for an OraVerse patient brochure. Earlier in the month, the agency issued letters to: Baumann Cosmetic and Research Institute, for promotion of Medicis and Ipsen's as-yet unapproved Dysport wrinkle filler; Bracco Diagnostics, for a website promoting its Isovue; GE Healthcare, for a website promoting its Visipaque Injection; and Lilly, for consumer print and journal ads promoting Cymbalta for fibromyalgia.

In 2009, DDMAC issued 41 enforcement letters, including 28 untitled letters and 13 warning letters. That's a big jump over 2008's 21 letters, including 10 untitled letters and 11 warning letters.


Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.